Table 1 Pretreatment parameters: Results of univariate analysis
Parameter | n (missing%) | Sphincter preservation, n (%) or mean value ± SD | Abdominoperineal resection, n (%) or mean value ± SD | p-value |
|---|---|---|---|---|
Overall | 280 (0%) | 158 (56.4%) | 122 (43.6%) | Â |
Mean age, years ± SD | 280 (0%) | 63.6 ± 11.6 | 67.4 ± 10.5 | 0.006 |
Gender | 280 (0%) | Â | Â | 0.096 |
 Male |  | 99 (62.7%) | 88 (72.1%) |  |
 Female |  | 59 (37.3%) | 34 (27.9%) |  |
Smoking | 237 (15.4%) | Â | Â | 0.640 |
 Yes |  | 27 (19.6%) | 17 (17.2%) |  |
 No |  | 111 (80.4%) | 82 (82.8%) |  |
Karnofsky performance status | 164 (41.4%) | Â | Â | 0.004 |
 100% |  | 76 (86.4%) | 51 (67.1%) |  |
  ≤ 90% |  | 12 (13.6%) | 25 (32.9%) |  |
Body mass index (mean ± SD) | 231 (17.5%) | 26.0 ± 4.6 | 26.4 ± 4.1 | 0.484 |
Clinical T- size | 280 (0%) | Â | Â | 0.018 |
 1–2 |  | 8 (5.1%) | 8 (6.6%) |  |
 3 |  | 136 (86.1%) | 89 (73.0%) |  |
 4 |  | 14 (8.9%) | 25 (20.5%) |  |
Histopathological subtype | 280 (0%) | Â | Â | 0.052 |
 Adenocarcinoma |  | 151 (95.6%) | 109 (89.3%) |  |
 Andenocarcinoma (mucinous) |  | 7 (4.4%) | 13 (10.7%) |  |
Histopathological tumor grading | 280 (0%) | Â | Â | 0.295 |
 1 |  | 10 (6.3%) | 6 (4.9%) |  |
 2 |  | 140 (88.6%) | 104 (85.2%) |  |
 3 |  | 8 (5.1%) | 12 (9.8%) |  |
Erythrocyte count (T/l) | 274 (2.1%) | 4.7 ± 47 | 4.6 ± 86 | 0.764 |
Erythrocyte value (groups) | 274 (2.1%) | Â | Â | 0.015 |
 below normal range (< 4.5) |  | 34 (21.9%) | 42 (35.3%) |  |
 normal/above range (≥4.5) |  | 121 (78.1%) | 77 (64.7%) |  |
Leucocyte count (G/l) | 275 (1.8%) | 7.8 ± 6.6 | 7.7 ± 2.4 | 0.853 |
Leucocyte value (groups) | 275 (1.8%) | Â | Â | 0.412 |
 normal range (≤11.3) |  | 148 (95.5%) | 113 (93.4%) |  |
 above normal range (> 11.3) |  | 7 (4.5%) | 8 (6.6%) |  |
Hemogobin value (g/dl) | 274 (2.1%) | 13.5 ± 1.8 | 13.2 ± 2.0 | 0.207 |
Hemogobin value (groups) | 274 (2.1%) | Â | Â | 0.154 |
 below normal range (< 13) |  | 38 (24.7%) | 39 (32.5%) |  |
 normal range (13–17.5) |  | 116 (75.3%) | 81 (67.5%) |  |
Thrombocyte count (G/l) | 271 (3.2%) | 278 ± 97 | 284 ± 97 | 0.601 |
Thrombocyte value (groups) | 271 (3.2%) | Â | Â | 0.399 |
 below normal range (< 140) |  | 142 (93.4%) | 114 (95.8%) |  |
 normal range (140–440) |  | 10 (6.6%) | 5 (4.2%) |  |
Absolute neutrophil value (G/l) | 243 (13.2%) | 4.9 ± 1.63 | 5.28 ± 2.09 | 0.078 |
Relative neutrophile value (%) | 230 (17.6%) | 66.3 ± 9.0 | 68.0 ± 7.8 | 0.092 |
Absolute lymphocyte value (G/l) | 265 (5.3%) | 1.63 ± 0.52 | 1.56 ± 0.54 | 0.272 |
Absolute lymphocte value (groups) | 265 (5.3%) | Â | Â | 0.835 |
 below normal range (< 1) |  | 13 (8.6%) | 9 (7.9%) |  |
 normal range (1–4.8) |  | 138 (91.4%) | 105 (92.1%) |  |
Relative lymphocyte value (%) | 273 (2.5%) | 23.32 ± 7.40 | 21.24 ± 6.98 | 0.021 |
Relative lymphocyte value (groups) | 268 (4.3%) | Â | Â | 0.199 |
 below normal range |  | 50 (32.9%) | 47 (40.5%) |  |
 normal range |  | 102 (67.1%) | 69 (59.5%) |  |
LDH value (U/l) | 259 (7.5%) | 190 ± 70 | 186 ± 52 | 0.793 |
LDH value (groups) | Â | Â | Â | 0.850 |
 normal range (≤240) |  | 130 (88.4%) | 98 (87.5%) |  |
 above normal range (> 240) |  | 17 (11.6%) | 14 (12.5%) |  |
CRP value (mg/l) | 255 (8.9%) | 6.2 ± 13.9 | 10.6 ± 22.8 | 0.003 |
CRP value (groups) | 255 (8.9%) | Â | Â | 0.008 |
 normal range (≤8) |  | 124 (85.5%) | 79 (71.8%) |  |
 above normal range (> 8) |  | 21 (14.5%) | 31 (28.2%) |  |
CEA value (ng/ml) | 200 (28.6%) | 6.94 ± 12.60 | 15.75 ± 78.96 | 0.339 |
CEA value (groups) | 200 (28.6%) | Â | Â | 0.601 |
 normal range (≤5) |  | 75 (67.6%) | 57 (64.0%) |  |
 above normal range (> 5) |  | 36 (32.4%) | 32 (36.0%) |  |
CA 19.9 value (U/ml) | 187 (33.2%) | 38.94 ± 126.57 | 18.06 ± 27.99 | 0.780 |
CA 19.9 value (groups) | 187 (33.2%) | Â | Â | 0.453 |
 normal range (≤37) |  | 91 (86.7%) | 74 (90.2%) |  |
 above normal range (> 37) |  | 14 (13.3%) | 8 (9.8%) |  |